PMID	chemical	trigger	target
25736031	Fructose	induce	insulin resistance
25736031	Fructose	alter	liver metabolism and gut barrier function
25736031	Citrulline	improve	insulin sensitivity
25736031	Glutamine	improve	insulin sensitivity
25736031	Arginine	improve	insulin sensitivity
25736031	fructose	alter	glucose homeostasis
25736031	Fructose	decrease	Bifidobacterium and Lactobacillus
25736031	Fructose	increase	endotoxemia
25736031	Citrulline	prevent	hypertriglyceridemia
25736031	Arginine	prevent	hypertriglyceridemia
25736031	Glutamine	prevent	hypertriglyceridemia
25736031	Citrulline	attenuate	liver fat accumulation
25736031	Arginine	attenuate	liver fat accumulation
25736031	Glutamine	attenuate	liver fat accumulation
25736031	nitrogen	attenuate	fructose-induced non-alcoholic fatty liver disease
25736031	Citrulline	attenuate	fructose-induced non-alcoholic fatty liver disease
25736031	Citrulline	prevent	hypertriglyceridemia and steatosis
26396156	carbohydrate	waste	disorders, metabolic disease, and nonalcoholic fatty liver disease
26396156	Pparα	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis
26396156	acyl-CoA oxidase	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis
26396156	Acox1	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis
26396156	hydroxy-3-methylglutaryl-CoA synthase 2	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis
26396156	Hmgcs2	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis
26396156	PCB126-induced	decrease	serum glucose caused by decreased hepatic glucose production
26396156	PCB126-induced	decrease	peroxisomal fatty acid oxidation
26640164	Tetracycline	cause	hepatic steatosis, and
26640164	bicyclol	attenuate	tetracycline-induced fatty liver
26640164	tetracycline	evaluate	liver injuries
26640164	serum ALT	evaluate	liver injuries
26640164	AST	evaluate	liver injuries
26640164	TG	evaluate	liver injuries
26640164	CHO	evaluate	liver injuries
26640164	bicyclol	alleviate	hepatic apoptosis and the gene expression of caspase-3
26640164	bicyclol	increase	the gene expression of XIAP
26640164	bicyclol	protect	tetracycline-induced fatty liver
27062444	Peroxisome proliferator-activated receptor gamma	regulate	lipogenesis and lipid accumulation
27062444	Lieber-DeCarli alcohol	control	liquid diet
27062444	maltose dextrin	control	liquid diet
27062444	hepatic PPARγ	alleviate	alcohol-induced lipid accumulation
27062444	hepatic PPARγ	abolish	the up-regulation of FASN, DGAT1, and DGAT2
27062444	FL83B cells	decrease	ethanol (EtOH)-, linoleic acid-, and EtOH plus linoleic acid-induced lipid accumulation
27108203	PFOS	increase	the transcriptional expression of nuclear receptors
27108203	PFOS	decrease	liver ATP content and serum level of VLDL/LDL lipoprotein in males
27108203	PFOS	induce	hepatic steatosis in zebrafish
27108203	PFOS	disturb	lipid biosynthesis, fatty acid β-oxidation and excretion of VLDL/LDL lipoprotein
27108203	PFOS	demonstrate	the validity of using zebrafish as an alternative model for PFOS chronic toxicity screening
27124661	ethanol	dysregulate	PTEN/Akt signaling
27124661	tensin homolog	possess	constitutive activation of Akt(s
27124661	tensin	possess	constitutive activation of Akt(s
27124661	tensin homolog	increase	de novo lipogenesis resulting in increased hepatocellular steatosis
27124661	tensin	increase	de novo lipogenesis resulting in increased hepatocellular steatosis
27124661	ethanol	increase	ALT, liver triglycerides and steatosis
27124661	ethanol	decrease	hepatocellular damage
27124661	ethanol	have	no effect in PTENLKO animals
27220557	FO	attenuate	the ethanol-induced hepatic lipid accumulation in mice
27220557	Ethanol	stimulate	adipose lipolysis
27220557	Ethanol	reduce	fatty acid/lipid uptake, which were normalized by FO
27220557	FO	normalize	lipid metabolism in adipose tissue
27220557	alcohol	stimulate	hepatic fatty acid uptake and triglyceride synthesis, which were attenuated by FO
27220557	FO	upregulate	plasma adiponectin concentration
27220557	FO	upregulate	hepatic adiponectin receptor 2 expression
27220557	FO	improve	lipid homeostasis
27614967	ginsenosides	reduce	TG content (9.69±0.22 μg/mg protein vs. 4.93±0.49 μg/mg protein, P<0.01), and ROS formation (7254.8±385.7 vs. 5825.2±375.9, P<0.01)
27614967	ginsenosides	down-regulate	CYP2E1 expression (P<0.01)
27614967	ginsenosides	upregulate	PPARα expression (P<0.01) in ethanol-treated cells
27614967	Ginsenosides	prevent	ethanol-induced hepatocyte steatosis in vitro related to the inhibition of oxidative stress and the improvement of mitochondrial function
27614967	CYP2E1	play	an important role
27614967	PPARα	play	an important role
27627966	alcohol	cause	hepatic lipid accumulation
27627966	alcohol	cause	hepatic lipid accumulation in Tlr4-wild-type mice but not in Tlr4-mutant mice
27692001	fatty liver	exhibit	hyperketonemia, oxidative stress,
27692001	AcAc	decrease	the mRNA expression and activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px),
27692001	AcAc	increase	malondialdehyde (MDA) content, indicative of oxidative stress
27692001	AcAc	down-regulate	the mRNA expression of apolipoprotein B100 (ApoB100), apolipoprotein E (ApoE), and low density lipoprotein receptor (LDLR), which thus decreased VLDL assembly
27692001	LDLR	decrease	VLDL assembly
27692001	AcAc	increase	triglyceride (TG) accumulation in these bovine hepatocytes
27692001	NAC	relieve	AcAc-induced oxidative stress
27692001	NAC	increase	VLDL assembly
27692001	VLDL	increase	TG accumulation in bovine hepatocytes
27837167	ligustrazine	attenuate	alcohol-induced hepatic steatosis and in vitro study
27837167	Nrf2	establish	Nrf2-knockdown mice
27837167	Nrf2	aggravate	alcoholic liver injury
27837167	Nrf2	abolish	the protective effect of ligustrazine, evidenced by elevated serum biomarkers and severe liver inflammation
27837167	Ligustrazine	ameliorate	hepatic steatosis
27837167	Ligustrazine	inhibit	hepatic sterol regulatory element-binding protein-1c and inducing peroxisome proliferator-activated receptor-alpha, which was abrogated by Nrf2 knockdown
27837167	Noteworthily	reinforce	the inductive effect of alcohol on hypoxia-inducible factor 1-alpha (HIF-1α)
27837167	Nrf2	reinforce	the inductive effect of alcohol on hypoxia-inducible factor 1-alpha (HIF-1α)
27837167	Ligustrazine	weaken	the stimulation of alcohol on HIF-1α expression, which was abrogated by Nrf2 shRNA lentivirus
27837167	Nrf2	abolish	the inhibitory effect of ligustrazine
27837167	dimethyloxalylglycine	abolish	the inhibitory effect of ligustrazine
27837167	HIF-1α	abolish	the inhibitory effect of ligustrazine
27837167	HIF-1α	mimic	the role of ligustrazine
27837167	Nrf2	mimic	the role of ligustrazine
27837167	dimethyloxalylglycine	mimic	the role of ligustrazine
27837167	HIF-1α	mimic	the role of ligustrazine
27837167	HIF-1α	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes
27837167	Nrf2	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes
27837167	dimethyloxalylglycine	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes
27837167	HIF-1α	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes
27837167	ligustrazine	attenuate	alcohol-induced hepatic steatosis
28131861	Cyp2a5	feed	the Lieber-Decarli ethanol diet
28131861	Cyp2a5 Mice	feed	the Lieber-Decarli ethanol diet
28131861	Cyp2a5	induce	alcoholic fatty liver
28131861	Cyp2a5 Mice	induce	alcoholic fatty liver
28366540	VPA	enhance	the efficiency of fatty acid uptake mediated by CD36
28366540	VPA	increase	DGAT2 expression
28366540	DGAT2	alleviate	VPA-induced intracellular lipid accumulation
28366540	CD36	offer	novel therapeutic strategies to combat VPA-induced hepatotoxicity
28366540	DGAT2	offer	novel therapeutic strategies to combat VPA-induced hepatotoxicity
28449683	FK866	promote	liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro
28449683	NAMPT	aggravate	the HFD- or oleic acid-induced hepatic steatosis
28449683	Nicotinamide	aggravate	the HFD- or oleic acid-induced hepatic steatosis
28449683	NMN	aggravate	the HFD- or oleic acid-induced hepatic steatosis
28449683	NAD	aggravate	the HFD- or oleic acid-induced hepatic steatosis
28449683	Nicotinamide mononucleotide	aggravate	the HFD- or oleic acid-induced hepatic steatosis
28449683	NAMPT	suppress	Sirt1-mediated signaling pathway
28449683	Nicotinamide	suppress	Sirt1-mediated signaling pathway
28449683	NMN	suppress	Sirt1-mediated signaling pathway
28449683	NAD	suppress	Sirt1-mediated signaling pathway
28449683	Nicotinamide mononucleotide	suppress	Sirt1-mediated signaling pathway
28449683	NAMPT	reduce	the production of NAD
28465000	aspartame	induce	hyperglycemia and hypertriacylglycerolemia
28465000	adiponectin	activate	receptor-γ (PPAR-γ) expression
28777337	Tunicamycin	develop	an anti-cancer drug
28777337	ER	develop	an anti-cancer drug
28777337	Tunicamycin	induce	a yellowish color and ER stress, as well as
28777337	Tunicamycin	increase	serum levels of aspartate transaminase and alanine transaminase
28777337	tunicamycin	increase	hepatic triglyceride content
28777337	tunicamycin	suppress	the expression of apolipoprotein B100
28777337	Tunicamycin	alter	hepatic energy homeostasis
28777337	Tunicamycin	increase	triglyceride accumulation
28777337	Tunicamycin	decrease	glycogen content
28803762	Alcohol	reverse	this disease
28803762	Apigenin	increase	the expression of hepatic peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase-1 proteins
28803762	Apigenin	decrease	the expression of hepatic sterol regulatory element binding protein-1c, fatty acid synthase, and diacylglycerol acyltransferase proteins
28803762	apigenin	exert	a protective effect
28933423	omega-3 PUFA	ameliorate	Hcy-induced hepatic steatosis
28933423	ceramide	ameliorate	hepatic lipid accumulation
28933423	omega-3 PUFA	ameliorate	hepatic lipid accumulation
28962527	Amiodarone	cause	liver steatosis
28962527	Amiodarone	reduce	intracellular ATP and Ca2
28962527	Amiodarone	induce	ER stress and lipid accumulation
28962527	amiodarone	increase	hepatic mRNA expression of lipid droplet proteins, particularly Cidea and Cidec, in WT, but
28962527	amiodarone	suggest	a link between ER stress
28962527	amiodarone	increase	triglyceride storage
28962527	insulin	attenuate	amiodarone-induced phosphorylation of hormone sensitive lipase (HSL) in WT
28962527	ER	reduce	lipid accumulation
28962527	ER	drive	liver steatosis
28987868	Protein kinase B	play	important roles
28987868	PKB/Akt	play	important roles
28987868	cytochrome P4502E1	play	causal roles
28987868	CYP2E1	play	causal roles
28987868	ethanol	have	no effects on the protein levels of phosphatidylinositol 3 kinase (PI3K) and phosphatase and tensin homologue deleted on chromosome ten (PTEN)
28987868	N-acetyl-L-cysteine	attenuate	chronic ethanol-induced hepatic fat accumulation and the decline of Akt phosphorylation at Thr308
28987868	NAC	attenuate	chronic ethanol-induced hepatic fat accumulation and the decline of Akt phosphorylation at Thr308
28987868	Akt	alleviate	chronic ethanol-induced fatty liver
28987868	insulin-like growth factor-1	alleviate	chronic ethanol-induced fatty liver
28987868	IGF-1	alleviate	chronic ethanol-induced fatty liver
29126901	LXR activator	induced	lipid accumulation and docosahexaenoic acid (DHA; a representative n-3 PUFA)
29126901	LXR activator	inhibit	lipid accumulation
29126901	DHA	inhibit	T0901317-induced lipid accumulation in primary hepatocytes from wild type mice, but not in those from FFA4 deficient mice
29169220	HepG2 cells	induce	lipogenesis and accumulation of intracellular lipid contents
29169220	HepG2 cells	increase	the expression of SREBP-1
29169220	PA	increase	the expression of SREBP-1
29169220	estrogen	increase	the expression of SREBP-1
29169220	genistein	increase	the expression of SREBP-1
29404450	intracellular	play	a key role
29404450	hepatocytes	contain	juxtanuclear lysosomes that exhibited impaired motility
29404450	juxtanuclear lysosomes	exhibit	impaired motility
29457836	alcohol	cause	hepatic lipid accumulation
29457836	rapamycin complex 1	play	a causal role
29457836	rapamycin	play	a causal role
29457836	hepatic DEPTOR	suppress	mTORC1 signaling
29457836	hepatic DEPTOR	ameliorate	alcoholic hepatosteatosis, inflammation, and acute-on-chronic liver injury
29457836	mTORC1	attenuate	alcohol-induced cytoplasmic accumulation of the lipogenic regulator lipin 1
29457836	mTORC1	prevent	alcohol-mediated inhibition of fatty acid oxidation
29457836	rapamycin	alleviate	the ability of alcohol to up-regulate lipogenesis
29457836	rapamycin	down-regulate	fatty acid oxidation
29457836	rapamycin	induce	steatogenic phenotypes
29457836	hepatocyte-specific	disrupt	DEPTOR function
29457836	SIRT1	disrupt	DEPTOR function
29457836	hepatocyte-specific	enhance	mTORC1 activity
29457836	SIRT1	enhance	mTORC1 activity
29526820	benzbromarone	induce	hepatic toxicity in patients
29526820	benzbromarone	aggravate	hepatic steatosis in both obese db/db mice and high fat diet (HFD)-induced obese (DIO) mouse models
29526820	benzbromarone	have	less effect on the liver of lean mice
29526820	benzbromarone	promote	intracellular lipid accumulation under high free fatty acids (FFAs) conditions
29526820	benzbromarone	regulate	the expression of lipid metabolism genes
29526820	benzbromarone	increase	cell apoptosis in HepG2 cells
29526820	benzbromarone	aggravate	hepatic steatosis in obese individuals,
29526820	benzbromarone	suggest	a novel toxicological mechanism in benzbromarone-induced hepatotoxicity
29529605	AMPKα	increase	the expression and transcriptional activity of peroxisome proliferator-activated receptor α
29529605	AMPKα	upregulate	the expression of lipid oxidation genes
29529605	element-binding protein 1c	reduce	the expression of lipogenic genes
29529605	acetic acid	activate	the AMPKα signalling pathway
29529605	acetic acid	decrease	lipid synthesis in BRL-3A cells
29529605	acetic acid	reduce	liver fat accumulation
29587622	Diacylglycerol acyltransferase 1	catalyze	the final step in triglyceride synthesis
29587622	Diacylglycerol	catalyze	the final step in triglyceride synthesis
29597210	Saturated fatty acid palmitate	stimulate	lipid accumulation and apoptosis in hepatocytes
29597210	Palmitate	induce	lipid accumulation and mRNA expression of lipogenic genes such as SREBP1c and SCD1
29597210	palmitate	stimulate	caspase-3 activity
29597210	palmitate	decrease	cell viability
29597210	AMP-activated protein kinase	abolish	the effects of BO
29597210	BO	attenuate	palmitate-induced hepatic steatosis and apoptosis
29625129	miR-378	impair	FAO
29625129	miR-378	promote	lipid accumulation in murine hepatoma Hepa1-6 cells
29625129	miR-378	improve	FAO
29625129	miR-378	reduce	intracellular lipid content in Hepa1-6 cells
29625129	Liver-specific	impair	FAO, which subsequently promoted the development of hepatosteatosis
29625129	miR-378	impair	FAO, which subsequently promoted the development of hepatosteatosis
29625129	miR-378	promote	the development of hepatosteatosis
29625129	Nrf1	offset	the effects of miR-378-ASO
29625129	Nrf1	mediate	the inhibitory effect of miR-378-ASO on hepatosteatosis
29625129	Nrf1	mediate	the inhibitory effect of miR-378-ASO on hepatosteatosis
29625129	Nrf1	promote	the pathogenesis of hepatosteatosis
29630881	aldose reductase	ameliorate	alcoholic hepatic steatosis
29630881	AR	improve	alcoholic hepatic steatosis
29630881	AR	feed	a Lieber-DeCarli liquid diet
29630881	AR	affect	carbohydrates and peptides
29630881	AR	impair	galactose metabolism
29630881	galactose	impair	galactose metabolism
29630881	fatty acid	impair	galactose metabolism
29630881	AR	perturb	fatty acid biosynthesis
29630881	galactose	perturb	fatty acid biosynthesis
29630881	fatty acid	perturb	fatty acid biosynthesis
29630881	AR	suppress	ethanol-activated galactose metabolism and saturated fatty acid biosynthesis
29630881	sorbitol	augment	ethanol-induced steatosis and stearic acid
29704577	lipids	modify	energy metabolism, hepatic structure and function
29704577	steroids	modify	energy metabolism, hepatic structure and function
29704577	AS	reduce	plasma HDL cholesterol levels
29782848	alcohol	affect	these processes
29782848	TFEB	regulate	lysosomal biogenesis
29782848	alcohol	evaluate	the functions of transcription factor EB (TFEB), which regulates lysosomal biogenesis
29782848	liver-specific	have	lower levels of total and nuclear TFEB
29782848	TFEB	have	lower levels of total and nuclear TFEB
29782848	Tefb	have	lower levels of total and nuclear TFEB
29782848	Tfe3	have	lower levels of total and nuclear TFEB
29782848	TFEB	have	lower levels of total and nuclear TFEB
29782848	TFE3	have	lower levels of total and nuclear TFEB
29782848	Tfeb Liver tissues	have	lower levels of total and nuclear TFEB
29782848	ethanol	have	lower levels of total and nuclear TFEB
29782848	hepatocytes	decrease	lysosome biogenesis and autophagy
29782848	liver-specific	decrease	lysosome biogenesis and autophagy
29782848	TFEB	decrease	lysosome biogenesis and autophagy
29782848	Tefb	decrease	lysosome biogenesis and autophagy
29782848	Tfe3	decrease	lysosome biogenesis and autophagy
29782848	TFEB	decrease	lysosome biogenesis and autophagy
29782848	TFE3	decrease	lysosome biogenesis and autophagy
29782848	Tfeb Liver tissues	decrease	lysosome biogenesis and autophagy
29782848	ethanol	decrease	lysosome biogenesis and autophagy
29782848	Hepatocytes	increase	translocation of mTOR into lysosomes
29782848	ethanol	increase	translocation of mTOR into lysosomes
29782848	torin-1	increase	liver levels of TFEB
29782848	torin-1	decrease	steatosis and liver injury induced by ethanol
29782848	TFEB	develop	less severe ethanol-induced liver injury
29782848	TFEB	increase	lysosomal biogenesis and mitochondrial bioenergetics
29782848	TFEB	develop	more severe liver injury
29782848	TFEB-TFE3	develop	more severe liver injury
29782848	Liver tissues	have	 lower nuclear levels of TFEB than control tissues
29782848	ethanol	decrease	hepatic expression of TFEB, which is required for lysosomal biogenesis and autophagy
29782848	mTOR	protect	the liver
29782848	TFEB	protect	the liver
29934713	Lipin-1	perform	dual function
29934713	exendin-4	prevent	endoplasmic reticulum (ER) stress-induced hepatic steatosis
29934713	Exendin-4	decrease	the expression of ER stress markers
29934713	Exendin-4	decrease	glucose-regulated protein 78 kDa (GRP78) proteins and spliced X-box binding protein 1 (XBP-1s) mRNA
29934713	Exendin-4	phosphorylate	PKR like ER kinase (PERK), phosphorylated inositol-requiring enzyme 1 alpha (IRE1α)
29934713	Exendin-4	increase	the expression of genes encoding lipolytic enzymes hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL) and VLDL assembly-associated proteins microsomal triglyceride transfer protein (MTP) and apolipoprotein B (APOB) in tunicamycin-pretreated cells
29934713	exendin-4	decrease	lipin-1β/α ratio
29934713	exendin-4	increase	SFRP10
29934713	exendin-4	increase	lipin-1 nuclear localization
29934713	exendin-4	improve	ER stress-induced hepatic lipid accumulation
29934713	exendin-4	increase	lipolysis and VLDL assembly
30138652	Nanoparticle	promote	hepatic steatosis
30138652	Nanoparticle	investigate	the influence of multi-walled carbon nanotubes (MWCNTs) on lipid accumulation in hepatocytes
30138652	MWCNTs	accompany	cytotoxicity, lysosomal destabilization, and intracellular reactive oxygen species (ROS) production
30138652	carboxylated MWCNTs	accompany	cytotoxicity, lysosomal destabilization, and intracellular reactive oxygen species (ROS) production
30214048	JMJD2B	stimulate	the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its steatosis target genes associated with fatty acid uptake and lipid droplet formation
30214048	HepG2 cells	stimulate	the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its steatosis target genes associated with fatty acid uptake and lipid droplet formation
30214048	JMJD2B	feed	a HFD, which was accompanied with increased expression of hepatic PPARγ2 and its steatosis target genes
30248338	hepatocyte VDR	set	steatosis
30248338	ANGPTL8	attenuate	free fatty acids-induced triglyceride accumulation in these cells
30248338	fatty acids	up-regulate	both VDR and ANGPTL8 mRNA
30248338	insulin	up-regulate	both VDR and ANGPTL8 mRNA
30248338	VDR	up-regulate	ANGPTL8 expression
30248338	hepatic ANGPTL8	play	a key role
30452912	Doxorubicin	disturb	the lipid metabolism
30452912	doxorubicin	impede	lipogenesis and elevated lipolysis
30452912	Doxorubicin	impair	the lipogenesis through PPARγ
30452912	Doxorubicin	augment	lipolysis and fatty acid oxidation through ATGL and PPARα
30452912	Apo B	develop	insulin resistance and hepatic steatosis condition
30452912	fatty acid	dysregulate	AHR, PXR, PPARγ, ATGL and Apo B,which further develop insulin resistance and hepatic steatosis condition
30452912	adipose tissue	dysregulate	AHR, PXR, PPARγ, ATGL and Apo B,which further develop insulin resistance and hepatic steatosis condition
30557836	Dipeptidyl peptidase-4	exert	beneficial effects against insulin resistance (IR) and type 2 diabetes
30557836	DPP-4	ameliorate	COC-induced glucose dysregulation and hepatic triglyceride (TG) accumulation through adenosine deaminase (ADA) /xanthine oxidase (XO) /uric acid-dependent pathway
30557836	COC	result	in increased plasma and hepatic TG, TG/HDL-cholesterol ratio, malondialdehyde, uric acid (plasma; 25.2 ± 0.6 mg/dl; hepatic 128.9 ± 8.0 mg/100 mg tissue), lactate dehydrogenase, DPP-4, ADA and XO (plasma;10.5 ± 1.1 U/L; hepatic 21.2 ± 1.4 U/g protein) activities
30557836	DPP-4	ameliorate	these alterations induced by COC treatment through suppression of uric acid (plasma; 15.1 ± 1.0 mg/dl, hepatic; 75.6 ± 5.0 mg/100 mg tissue), XO (plasma;
30557836	DPP-4	ameliorate	4.1 ± 0.9 U/L, hepatic; 8.7 ± 0.4 U/g protein), ADA and DPP-4 activities suggesting their involvement in glucose dysregulation and hepatic TG accumulation induced by COC treatment
30562559	p70 ribosomal protein subunit 6 kinase 1	improve	hepatic steatosis
30677459	cell	study	the impact of efavirenz on PXR activities and lipid homeostasis
30677459	efavirenz	activate	PXR
30677459	efavirenz	induce	its target gene expression
30677459	hepatic PXR	abolish	these adverse effects
30677459	PXR	regulate	the expression of several key hepatic lipogenic genes including fatty acid transporter CD36 and cholesterol biosynthesis enzyme squalene epoxidase (SQLE)
30677459	PXR	exhibit	considerable differences in its pharmacology across species
30677459	efavirenz	induce	hypercholesterolemia and hepatic steatosis
30677459	efavirenz	activate	PXR signaling
30677459	efavirenz	activate	a unique liver protein called PXR which mediates the adverse effects of efavirenz on lipid levels in mouse models
30677459	PXR	mediate	the adverse effects of efavirenz on lipid levels in mouse models
30824780	Cell	add	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
30824780	Silybin	ameliorate	the harmful BPA-induced effect decreasing glucose uptake and lipid peroxidation
30824780	silybin	activate	the synthesis of vitamin D3 metabolites
30824780	silybin	prevent	the steroid hormones oxidation
30880507	Metformin	inhibit	gluconeogenesis and glycogenolysis in hepatocytes
30880507	Metformin	limit	lipid storage in the liver
30880507	endocannabinoids	modulate	hepatosteatosis
30880507	metformin	modulate	hepatosteatosis
30880507	metformin	affect	lipid accumulation in hepatocytes
30880507	intracellular lipids	use	Oil-Red-O staining
30880507	AM1241	treat	Hep3B cells
30880507	H-indol-3-yl]methanone	treat	Hep3B cells
30880507	Met	decrease	lipid accumulation in cells treated with OA
30880507	Met	inhibit	CB1R agonist-induced lipid accumulation in hepatocytes
30880507	metformin	inhibit	CB1R agonist-stimulated fat accumulation in hepatocytes
31026768	Vinyl chloride	cause	steatohepatitis
31026768	Mitochondrial	play	key roles
31026768	Mitochondrial	mediate	this interaction
31026768	low-dose	cause	liver injury
31026768	VC	decrease	hepatic ALDH2 activity of mice
31026768	VC	feed	HFD
31026768	Alda-1	attenuate	oxidative stress, liver injury, and dysmetabolism in mice exposed to HFD+VC under these conditions
31026768	Alda-1	suppress	PINK1/PARKIN-mediated mitophagy
31026768	ALDH2	confer	protection against liver damage under these conditions
31026768	Alda-1	confer	protection against liver damage under these conditions
31053639	dexamethasone	induce	the rate of hepatic
31151157	Thioacetamide	induce	lipid accumulation in the liver
31330194	dexamethasone	induce	steatosis
31463983	vitamin D	establish	an animal model of vitamin D deficiency
31463983	vitamin D	induce	hepatic lipid accumulation
31463983	vitamin D	reduce	alcohol-induced triacylglycerol (TAG) content
31463983	vitamin D deficiency	reduce	alcohol-induced triacylglycerol (TAG) content
31463983	vitamin D	prevent	hepatic lipid accumulation
31463983	vitamin D deficiency	prevent	hepatic lipid accumulation
31463983	vitamin D	attenuate	alcohol-induced sterol-regulated element-binding protein (SREBP)-1c activation, which regulates genes for hepatic fatty acid (FA) and TAG synthesis
31463983	vitamin D	attenuate	the expression of its target genes fatty acid synthase (Fasn) and acetyl-coenzyme- A carboxylase (Acc)
31463983	sterol-regulated element-binding protein (SREBP)-1c	regulate	genes for hepatic fatty acid (FA) and TAG synthesis
31463983	vitamin D	alleviate	alcohol-induced downregulation of hepatic nuclear peroxisome proliferator-activated receptor (PPAR)α, which governs FA transport and β-oxidation
31463983	hepatic nuclear peroxisome proliferator-activated receptor	govern	FA transport and β-oxidation
31463983	Vitamin D	alleviate	acute alcohol-induced hepatic lipid accumulation
31463983	Vitamin D	inhibit	hepatic de novo fatty acid syntheses
31463983	Vitamin D	promote	fatty acid β-oxidation and ω-oxidation
31470036	Bisphenol A	increase	cholesterol levels
31470036	BPA	increase	cholesterol levels
31470036	plasticizers	increase	cholesterol levels
31470036	BPA	increase	hepatic cholesterol content
31470036	BPA	decrease	the DNA methylation levels of SREBP-2
31470036	DNA	decrease	the DNA methylation levels of SREBP-2
31470036	BPA	increase	the expression levels of SREBP-1c and stearoyl-CoA desaturase 1 in the liver
31470036	BPA	induce	hepatic lipid synthesis and fat accumulation
31470036	low-dose	induce	hepatic cholesterol synthesis
31470036	BPA	induce	hepatic cholesterol synthesis
31470036	cholesterol	cause	cholesterol accumulation
31470036	low-dose	decrease	the DNA methylation levels of SREBP-2
31470036	BPA	decrease	the DNA methylation levels of SREBP-2
31470036	low-dose	induce	liver lipid synthesis and hepatic steatosis
31470036	BPA	induce	liver lipid synthesis and hepatic steatosis
31470036	low-dose	up-regulate	the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation
31470036	BPA	up-regulate	the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation
31473330	steroid	modulate	multiple physiological processes in teleosts
31473330	E2	upregulate	TC, TG, LDL, and HDL
31473330	E2	show	a significantly higher expression of the VLDL assembly genes but depressed levels of LDLR and LRP1
31473330	ICI	inhibit	the expression of MTP, LPL, LRP1, CD36, FABP11a, ACO1 and FAS in tilapia livers
31473330	E2	induce	deposition of lipids in the livers of hybrid tilapia
31473330	E2	stimulate	the expression of genes associated with the VLDL assembly
31473330	E2	inhibit	lipoprotein lipase and lipoprotein receptor-related genes
31473330	E2	promote	the rate-limiting enzyme in the synthesis of the TG
31473330	E2	provide	new clues to illustrate the sex steroid function in energy metabolism in livers
31491605	Mono-2-ethylhexyl phthalate	induce	lipid accumulation in hepatocytes
31491605	MEHP	induce	lipid accumulation in hepatocytes
31491605	DEHP	induce	lipid accumulation in hepatocytes
31491605	Di-(2-ethylhexyl	induce	lipid accumulation in hepatocytes
31491605	phthalate	induce	lipid accumulation in hepatocytes
31491605	MEHP	promote	the lipid synthesis and accumulation in BRL-3A cells
31491605	MEHP	down-regulate	the expression
31491605	MEHP	inhibit	the activation of JAK2/STAT5
31491605	MEHP	inhibit	JAK2/STAT5 pathway
31682409	Cd	induce	NAFLD
31682409	Cd	cause	marked hepatic mitochondrial dysfunction and fatty acid oxidation deficiency, along with significant suppression of sirtuin 1 (SIRT1) signaling pathway in the liver
31682409	Cd	inhibit	the mitochondrial fatty acid oxidation in hepatocytes
31682409	Cd	deserve	greater attention
31857090	xanthine oxidase	exert	both inflammatory and oxidative effects
31857090	xanthine	exert	both inflammatory and oxidative effects
31857090	SCFAs	elicit	beneficial metabolic alterations in IR and related syndromes
31857090	fatty acids (SCFAs	elicit	beneficial metabolic alterations in IR and related syndromes
31857090	nicotine	increase	fasting plasma glucose, lactate, IR, plasma and hepatic TG, free fatty acid, TG/HDL-cholesterol ratio, lipid peroxidation, liver function enzymes, plasma and hepatic UA, XO and ADA activities
31857090	acetate	ameliorate	nicotine-induced effects
31857090	nicotine	enhance	XO activity
31857090	acetate	confer	hepatoprotection
31866205	SFAs	maintain	cell metabolic hemostasis
31866205	PA	induce	lipotoxic effects
31866205	PA	induce	lipotoxic effects
31866205	LPA	induce	lipotoxic effects
31866205	PA	increase	mitochondrial functions
31866205	LPA	increase	mitochondrial functions
31866205	PA	alleviate	the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
31866205	LPA	alleviate	the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
32165129	valproate	impaired	lipid droplet disposal starting at 1 mM after incubation for 3 or 7 days
32165129	Valproate	increase	the expression of genes associated with fatty acid import and triglyceride synthesis
32165129	Valproate	affect	expression of genes engaged in fatty acid activation
32165129	Valproate	impair	mitochondrial fatty acid metabolism
32165129	Valproate	inhibit	β-ketothiolase
32165129	Valproate	increase	the mitochondrial DNA copy number per HepaRG cell,
32165129	Valproate	decrease	the hepatocellular mRNA and protein expression of the fatty acid binding protein 1 (FABP1) and of the microsomal triglyceride transfer protein (MTTP)
32165129	Valproate	increase	the hepatocellular concentration of free fatty acids
32165129	valproate	decrease	protein expression and excretion of ApoB100 in HepaRG cells
32165129	valproate	reflect	impaired formation and excretion of very low-density lipoprotein (VLDL)
32165129	valproate	increase	the hepatocellular triglyceride content
32165129	Valproate	cause	cell death
32165129	Valproate	increase	hepatocellular concentration of free fatty acids
32231762	Mitochondrial	examine	High AA
32231762	DHA	decrease	mitochondrial activity ( High AA:
32231762	DHA	induce	triglyceride accumulation
32231762	DHA	induce	triglyceride accumulation
32231762	DHA	increase	oxidative stress
32231762	DHA	increase	oxidative stress
32231762	DHA	disrupt	mitochondrial functions
32231762	DHA	disrupt	mitochondrial functions
32231762	steroidal transcription factors	mediate	these effects
32324591	SCD1	regulate	lipophagy in hepatic steatosis
32324591	hepatic steatosis	investigate	the molecular mechanisms through which SCD1 regulates lipophagy in hepatic steatosis
32324591	hepatic steatosis	induce	mouse primary hepatocytes with sodium palmitate and feeding C57BL/6 mice with HFD
32324591	sodium palmitate-treated hepatocytes	increase	SCD1 expression, AMPK inactivation and defective lipophagy
32324591	SCD1	reduce	lipid deposition
32324591	hepatocytes	reduce	lipid deposition
32324591	SCD1	regulate	lipophagy
32324591	SCD1	affect	lipid metabolism
32324591	CAY10566(an	decrease	hepatic steatosis and hepatic lipid droplet accumulation, as well as enhanced AMPK activity and lipophagy
32324591	SCD1	ameliorate	hepatic steatosis
32324591	SCD1	induce	AMPK-mediated lipophagy
32410680	nicotinamide adenine dinucleotide	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days
32410680	NAD 12 C57BL/6	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days
32410680	nicotinamide adenine	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days
32410680	NAD	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days
32410680	tetradecylthiopropionic acid	induce	fatty liver accompanied by decreased mitochondrial fatty acid oxidation
32410680	NAD Fatty liver	decrease	the levels of kynurenine metabolites
32410680	tetradecylthiopropionic acid	decrease	the levels of kynurenine metabolites
32410680	NAD	decrease	the levels of kynurenine metabolites
32410680	NAD Fatty liver	increase	the plasma levels of NAD
32410680	tetradecylthiopropionic acid	increase	the plasma levels of NAD
32410680	NAD	increase	the plasma levels of NAD
32493774	rapeseed	cause	hepatic steatosis in animals
32493774	erucic acid	cause	hepatic steatosis in animals
32493774	Mitochondrial fatty acid	play	a central role
32493774	fatty acid	play	a central role
32493774	erucic acid	decrease	mitochondrial fatty acid oxidation
32493774	peroxisomal	stimulate	malonyl-CoA formation in the liver
32493774	erucic acid	stimulate	malonyl-CoA formation in the liver
32493774	peroxisomal	suppress	mitochondrial fatty acid oxidation
32493774	erucic acid	suppress	mitochondrial fatty acid oxidation
32585865	DZA	increase	hepatocellular triglyceride accumulation, which was also evident by morphological visualization of larger-sized LDs
32585865	triglycerides	accompany	increases in mRNA and protein levels of several LD-associated proteins known to regulate LD number and size
32585865	LDs	accompany	increases in mRNA and protein levels of several LD-associated proteins known to regulate LD number and size
32585865	DZA	cause	a decline in the levels of lipases that prevent fat accumulation as well as
32585865	DZA	prevent	fat accumulation as well as
32585865	DZA	increase	the expression of factors involved in lipogenesis and fatty acid mobilization
32585865	intracellular SAH	promote	fat accumulation in hepatocytes, which is similar to that seen after alcohol exposure
32593710	Bisphenol	impair	glucose and lipid metabolism
32593710	endocrine	modulate	these processes
32593710	endocrine	increase	the risk for metabolic diseases
32593710	BPA	cause	mild steatosis in OVX CBPA females
32593710	BPA	increase	the hepatic total lipids and mRNAs for Srebf1, Scd1, Hspa5, Hyou1 and Atf6
32593710	BPA	aggravate	hepatic steatosis in OVX mice
32593710	BPA	cause	NAFLD progression, which was partly mediated by chronic ER stress and the TGF-β1 pathway
32623605	VPA	cause	liver toxicity and steatosis through mitochondrial dysfunction
32623605	VPA	affect	oxygen consumption rates (OCRs)
32623605	VPA	cause	mitochondrial dysfunction
32623605	TFs	rescue	VPA-induced mitochondrial dysfunction
32623605	PHHs	identify	24 genuine C/EBPα target genes that are regulated in response to prolonged VPA exposure in PHHs
32687983	MC-LR	impact	liver health
33007364	VPA	cause	steatosis
33022571	Phe	have	severe effects
33022571	Phenanthrene	have	severe effects
33022571	polycyclic aromatic hydrocarbons	have	severe effects
33022571	chemicals	disturb	intestinal microbiota, which plays a vital role in lipids metabolism
33022571	chemicals	play	a vital role
33022571	Phe	disrupt	the intestinal microbiota
33022571	Phe	induce	significant alteration in relative Bacteroidetes, Firmicutes and Proteobacteria abundance in male mice
33022571	Phe	alter	the composition of gastrointestinal bacteria
33022571	Phe	induce	hepatic lipid metabolism disorder
33105604	insulin receptor	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice
33105604	IGF-1 receptor	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice
33105604	IGF1R	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice
33105604	OSI-906	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice
33105604	IR/IGF1R	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice
33105604	Linagliptin	improve	OSI-906-induced hepatic steatosis
33105604	Linagliptin	alter	glucose levels
33105604	Linagliptin	alter	free fatty acid levels, gluconeogenic gene expressions in the liver, or visceral fat atrophy
33105604	linagliptin	improve	hepatic steatosis induced by IR and IGF1R inhibition via a previously unknown mechanism that did not involve gluconeogenesis, lipogenesis, or inflammation
33105604	IGF1R	involve	gluconeogenesis, lipogenesis, or inflammation
33105604	linagliptin	suggest	the non-canonical actions of DPP-4 inhibitors in the treatment of hepatic steatosis under insulin-resistant conditions
33184849	conjugated linoleic acid	induce	an enlarged liver, hepatic steatosis
33184849	CLA	induce	an enlarged liver, hepatic steatosis
33184849	GW6471	block	PPARα binding to Acaca and Acads
33184849	PPARα	block	PPARα binding to Acaca and Acads
33184849	GW6471	abolish	the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes
33184849	PPARα	abolish	the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes
33302084	glyphosate	raise	potential environmental threats and public health concerns
33302084	GLY	raise	potential environmental threats and public health concerns
33302084	pro-	clarify	their roles
33302084	lipid	clarify	their roles
33302084	samples	clarify	their roles
33302084	Lipid	reduce	lipolysis-related gene expression levels, and resultant hepatic lipid accumulation
33302084	GLY	induce	hepatotoxicity in fish
33449950	O-1	stimulate	adipose triglyceride lipase (ATGL)
33449950	FoxO1	stimulate	adipose triglyceride lipase (ATGL)
33449950	O-1	suppress	its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver
33449950	FoxO1	suppress	its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver
33449950	Palmitate	promote	lipid accumulation
33449950	Palmitate	inhibit	lipid decomposition in human HepG2 hepatoma cells
33449950	Palmitate	reduce	FoxO1, ATGL and its activator comparative gene identification-58 (CGI-58) expression
33449950	Palmitate	increase	peroxisome proliferator-activated receptorγ (PPARγ) and its target gene G0S2 expression
33449950	FoxO1	increase	palmitate-inhibited ATGL and CGI-58 expression
33449950	FoxO1	reduce	palmitate-stimulated PPARγ and its target gene G0S2 expression
33449950	FoxO1	inhibit	lipid accumulation
33449950	FoxO1	promote	lipolysis in palmitate-treated hepatocytes
33449950	FoxO1-mediated	protect	hepatocytes
33762794	body	demonstrate	the potential adverse effects of these substances, including its effect on the development of non-alcoholic fatty liver disease, as one of the most prevalent chronic liver diseases
33762794	μmol/L	increase	the triglyceride level
33900847	Uox-KO	develop	hyperuricemia and aberrant lipid-metabolism
34128319	Rosiglitazone	exert	dual effects on liver steatosis
34128319	Rosiglitazone	exacerbate	liver steatosis
34128319	FABP4	alleviate	rosiglitazone-induced liver steatosis
34128319	I-9	alleviate	rosiglitazone-induced liver steatosis
34128319	FABP4 inhibitor I-9	alleviate	rosiglitazone-induced liver steatosis
34128319	I-9	decrease	rosiglitazone-induced increase in serum FABP4 level
34128319	FABP4	ameliorate	rosiglitazone-exacerbated elevated serum FABP4 level
34128319	FABP4	ameliorate	ectopic liver fat accumulation in obese diabetic db/db mice
34128319	I-9	ameliorate	rosiglitazone-exacerbated elevated serum FABP4 level
34128319	I-9	ameliorate	ectopic liver fat accumulation in obese diabetic db/db mice
34128319	FABP4 inhibitor I-9	ameliorate	rosiglitazone-exacerbated elevated serum FABP4 level
34128319	FABP4 inhibitor I-9	ameliorate	ectopic liver fat accumulation in obese diabetic db/db mice
34128319	FABP4	affect	its anti-diabetic efficacy
34128319	I-9	affect	its anti-diabetic efficacy
34128319	FABP4 inhibitor I-9	affect	its anti-diabetic efficacy
34206460	clozapine	affect	weight,
34206460	chromium	feed	a high fat diet (HFD)
34206460	fatty liver	feed	a high fat diet (HFD)
34206460	glucose	feed	a high fat diet (HFD)
34206460	clozapine	gain	more weight
34206460	clozapine	gain	higher daily food efficiency; higher serum or hepatic triglyceride, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and creatinine levels; and higher hepatic lipid regulation marker expression
34206460	clozapine	exhibit	insulin resistance, poorer insulin sensitivity, greater glucose intolerance, and less Akt phosphorylation
34206460	clozapine	reduce	the thickness of retinal cell layers
34246650	Acetaminophen	aggravate	lipid deposition in the liver
34246650	APAP	aggravate	lipid deposition in the liver
34246650	Acetaminophen	cause	liver injury
34246650	APAP	cause	liver injury
34246650	CAV-1 stent-like domain	upregulate	CAV-1 expression
34246650	CSD	upregulate	CAV-1 expression
34246650	caveolin-1	upregulate	CAV-1 expression
34246650	CAV-1	interfere	RNA and
34246650	CAV-1	co-treate	L02 cells
34246650	CAV-1	reduce	lipid accumulation in L02 cells
34246650	CAV-1	activate	Pink-1/Parkin-related mitophagy
34267188	ethanol-fed	develop	severe hepatic steatosis and inflammation
34267188	Torin 1	suppress	mTORC1 activity
34267188	Torin	suppress	mTORC1 activity
34267188	Torin 1	ameliorate	ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice
34267188	Torin	ameliorate	ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice
34267188	fenofibrate	reverse	ethanol-induced liver steatosis and inflammation in Depdc5-LKO mice
34267188	PPARα	reverse	ethanol-induced liver steatosis and inflammation in Depdc5-LKO mice
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	induce	steatosis
34344994	TCDD	induce	steatosis
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	increase	hepatic uptake of dietary and mobilized peripheral fats
34344994	TCDD	increase	hepatic uptake of dietary and mobilized peripheral fats
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	inhibit	lipoprotein export
34344994	TCDD	inhibit	lipoprotein export
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	repress	β-oxidation
34344994	TCDD	repress	β-oxidation
34344994	TCDD	repress	straight-chain fatty acid oxidation gene expression in mice
34344994	fatty acid	inhibit	the activity of short chain enoyl-CoA hydratase (ECHS1)
34681291	TEB	cause	liver toxicity
34681291	cellular lipid	cause	liver toxicity
34681291	cells	show	lipid accumulation
34681291	HepG2 cells	show	lipid accumulation
34681291	TEB	increase	the nuclear translocation of peroxisome proliferator-activated receptors and the expression of lipid uptake and oxidation-related markers such as cluster of differentiation 36, fatty acid transport protein (FATP) 2, FATP5, and carnitine palmitoyltransferase 1
34681291	20-80	increase	the nuclear translocation of peroxisome proliferator-activated receptors and the expression of lipid uptake and oxidation-related markers such as cluster of differentiation 36, fatty acid transport protein (FATP) 2, FATP5, and carnitine palmitoyltransferase 1
34681291	20-80	induce	the loss of mitochondrial membrane potential and lower levels of microsomal triglyceride transfer protein in the cells
34681291	TEB	induce	lipid accumulation
34681291	TEB	alter	the expression of lipid-metabolizing molecules
34681291	TEB	impair	lipid metabolism
34685712	Cell	define	the causal role
34685712	Cell	underlie	mechanism of FFA-activated mTORC1 signaling in hepatocellular cell injury
34685712	palmitic acid	(pa)-induce	ER stress and suppression of LAMP2 and autophagy flux
34685712	rapamycin	reverse	such deleterious effects
34685712	ATF4	modulate	LAMP2
34685712	rapamycin	attenuate	mTORC1 activation and ER stress,
34685712	rapamycin	restore	LAMP2 protein
34685712	rapamycin	improve	autophagy
34685712	hepatic FFAs	play	a crucial role
34685712	FFAs	play	a crucial role
34685712	FFAs	represent	an important mechanism of FFA-induced hepatocellular injury
34685712	hepatic FFAs	activate	mTORC1 signaling
34685712	FFAs	activate	mTORC1 signaling
34801933	HepG2	enhance	lipid transport to the cell
34801933	dexamethasone	enhance	lipid transport to the cell
34801933	palmitate	enhance	lipid transport to the cell
34801933	Dexamethasone	alter	FA composition resulting in the elevated n-3 polyunsaturated fatty acid (PUFA) activity in DAG and TAG
34801933	palmitate	alter	FA composition resulting in the elevated n-3 polyunsaturated fatty acid (PUFA) activity in DAG and TAG
34801933	lipid	exacerbate	lipotoxicity in HepG2 cells
34801933	FA	exacerbate	lipotoxicity in HepG2 cells
34801933	dexamethasone	exacerbate	lipotoxicity in HepG2 cells
34836271	GEN	inhibit	hepatic triglyceride accretion triggered by estrogen deficiency
34836271	Genistein	inhibit	hepatic triglyceride accretion triggered by estrogen deficiency
34836271	GEN	downregulate	the levels of genes and proteins involved in lipogenesis, such as sterol-regulatory element-binding protein-1c (SREBP-1c), fatty acid synthase (FASN), and stearoyl-coenzyme A desaturase 1 (SCD1)
34836271	GEN	upregulate	the gene and protein levels of the regulation factors responsible for fatty acid β-oxidation, such as carnitine palmitoyltransferase 1α (CPT-1α) and peroxisome proliferator-activated receptor α (PPARα)
34836271	GEN	improve	hepatic lipid metabolism
34836271	GEN	activate	ERβ and further modulation of Akt/mTOR signals
34856412	farnesoid X receptor	regulate	fatty acid β-oxidation (FAO)
34856412	FXR	regulate	fatty acid β-oxidation (FAO)
34856412	farnesoid X receptor	maintain	bile acid, cholesterol and glucose homeostasis,
34856412	FXR	maintain	bile acid, cholesterol and glucose homeostasis,
34856412	fatty acids	use	an integrated metabolomic and transcriptomic analysis in control
34856412	FXR	use	an integrated metabolomic and transcriptomic analysis in control
34897744	fluoxetine	increase	the risk of metabolic diseases such as non-alcoholic fatty liver disease
34897744	Fluoxetine	increase	hepatic lipid accumulation
34897744	fluoxetine	alter	the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease
34897744	Fluoxetine	increase	mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ
